Drug Trial Radar · NCT03813784
A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy
Last checked: Nov 19, 2026Latest source record: Sep 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
885
Actual
Start
Mar 7, 2019
Primary completion
Jun 7, 2023
Study completion Jun 7, 2023
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 23, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, open-label, multi-center, phase III trial to evaluate the efficacy and safety of SHR-1210 plus capecitabine and oxaliplatin sequenced by SHR-1210 plus apatinib versus capecitabine and oxaliplatin as first-line therapy in patients with locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Conditions
- Gastric Cancer
- GastroEsophageal Cancer
Interventions
SHR-1210Drug
Subjects receive SHR-1210 intravenously, Dosage form: lyophilised powder, Strength: 200 mg /vial
CapecitabineDrug
1000 mg/m\^2 administered as continuous oral twice daily (BID) of each 3-week cycle.
OxaliplatinDrug
130 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle.
ApatinibDrug
250 mg administered as continuous oral once daily (QD) of each 3-week cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival (OS) of SHR-1210 in combination with capecitabine + oxaliplatin sequenced by SHR-1210+apatinib versus capecitabine + oxaliplatin in all subjects or programmed cell death ligand 1 (PD-L1) positive participantsTime frame: Up to 36 months after the first participant is randomized.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital, Peking University
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.